---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-22-000007"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T20:40:50.525190+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incyte Q3 product rev $713M (+20%); Jakafi guidance raised to $2.38-2.40B; Opzelura $38M

## Summary
- Total product revenues $713M (+20% YoY); Jakafi $620M (+13%); Opzelura $38M ($0 prior year).
- GAAP diluted EPS $0.50 (vs $0.82 YoY); Non-GAAP diluted EPS $0.60 (vs $1.18).
- Jakafi FY22 guidance low end raised to $2.38-2.40B; other Hem/Onc rev guidance lowered to $200-210M on FX.
- Pending acquisition of Villaris (auremolimab anti-IL-15Rβ mAb) for vitiligo; clinical start 2023.
- Pipeline: once-daily ruxolitinib XR PDUFA Mar 23, 2023; axatilimab cGVHD results mid-2023; povorcitinib Ph3 HS end-2022.

## SEC filing metadata
- accession: 0000879169-22-000007
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916922000007/0000879169-22-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916922000007/incy-20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-22-000007
- JSON: https://secwatch.observer/filing/0000879169-22-000007.json
- Plain text: https://secwatch.observer/filing/0000879169-22-000007.txt

## Key facts
- Earnings Releases
  INCYTE CORP reported third fiscal quarter ended September 30, 2022 results: revenue $713 million. Guidance raised.
  - Period: third fiscal quarter ended September 30, 2022
  - Revenue: $713 million
  - Guidance: raised
  - Result: reported results
  source text: Total net product revenues grew to $713 million (+20% Y/Y) as a result of strong Jakafi ® (ruxolitinib) and Opzelura TM (ruxolitinib) cream net product revenues – Jakafi net product rev enues of $620 million in Q3’22 (+13% Y/Y); raising the bottom end of full year guidance to a new range of $2.38 to $2.40 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/879169/000087916922000007/0000879169-22-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.